References
- Cancer statistics in Japan — 2003. http:www.ncc.go.jp/jp/statistics/ 2003/index.html
- Dune, B.G.M. (1986) "Staging and kinetics of multiple myeloma", Seminar in Oncology, 13, 300–309.
- Chronic Leukemia and Myeloma Task Force of the National Cancer Institute (1973) "Proposed guidelines for protocol studies. II. Plasma cell myeloma", Cancer Treatment Report, 4, 145–158.
- Kaplan, E. and Meier, P. (1966) "Nonparametric estimation from incomplete observation", Journal of American Statistic Association, 53, 457–481.
- Mantel, N. (1966) "Evaluation of survival data and two new rank order statistics arising in its consideration", Cancer Chemotherapy Report, 50, 165–170.
- Gehan, E.A. (1965) "A generalized Wilcoxon test for comparing arbitrarily singly-censored samples", Biometrika, 52, 203–223.
- Neuhauser, M. and Bretz, F. (2001) "Nonparametric all-pairs multiple comparisons", Biometrical Journal, 43, 571–580.
- Dune, B.G.M. and Salmon, S.E. (1975) "A clinical staging system for multiple myeloma", Cancer, 36, 842–854.
- Myeloma Trialists' Collaborative Group (1998) "Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials", Journal of Clinical Oncology, 16, 3832–3842.
- UK Myeloma Forum (2001) "Guideline: Diagnosis and manage-ment of multiple myeloma", British Journal of Haematology, 115, 522— 540.
- Kyle, A.R., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.O., Dispenzieri, A., et al. (2003) "Review of 1027 patients with newly diagnosed multiple myeloma", Mayo Clinic Proceedings, 78, 21— 33.
- MacLennan, I.C.M., Chapman, C., Kelly, D.J. for the MRC Working Party on Leukaemia in Adults (1992) "Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis", Lancet, 339, 200–215.
- Blade, J., San Miguel, J.F., Alcala, A., Maldonado, J., Sanz, M.A., Garcia-Conde, J., et al. (1993) "Alternating combination VMCP/ VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients", Journal of Clinical Oncology, 11, 1165–1171.
- Corso, A., Klersy, C., Lazzarino, M. and Bernasconi, C. (1998) "Multiple myeloma in younger patients: the role of age as prognostic factor", Annals of Hematology, 76, 67–72.
- Myeloma Trialists' Collaborative Group (2001) "Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients", British Journal of Haematology, 113, 1020— 1034.
- British Committee for Standards in Haematology (BCSH) Haema-tology/Oncology Task Force (2003) "Guideline. Thalidomide in multiple myeloma: Current status and future prospects", British Journal of Haematology, 120, 18–26.